National Institutes of Health (NIH)
National Cancer Institute (NCI)
Funding Opportunity Title
Collaborative Research in Integrative Cancer Biology and the Tumor Microenvironment (U01)
U01 Research Project – Cooperative Agreements
Reissue of PAR-09-026
Funding Opportunity Announcement (FOA) Number
Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.393, 93.394, 93.396
With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages new collaborative projects between investigators associated with the Integrative Cancer Biology Program (ICBP) or Tumor Microenvironment Network (TMEN) and researchers who are not involved with the program with which they propose to collaborate. This FOA is designed to facilitate new projects in integrative cancer biology and/or tumor microenvironment research and to extend current research conducted in the ICBP and TMEN programs through collaborations with a broader research community. Research projects proposed in response to this FOA should be collaborative and relevant to the missions of the ICBP or TMEN programs. In addition to proposing new research, these projects are expected to leverage the resources and expertise currently available within the ICBP and TMEN communities, in order to extend and enhance the programs with new ideas, methods, expertise, and resources.
March 16, 2011
Open Date (Earliest Submission Date)
|September 19, 2011|
Letter of Intent Due Date
September 19, 2011
Application Due Date(s)
October 19, 2011, by 5:00 PM local time of applicant organization.
AIDS Application Due Date(s)
Scientific Merit Review
Advisory Council Review
Earliest Start Date(s)
October 20, 2011
Due Dates for E.O. 12372
Required Application Instructions
It is critical that applicants follow the instructions in the SF 424 (R&R) Application Guide except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.
Part 1. Overview Information
Part 2. Full Text of the Announcement
Section I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information
The purpose of this Funding Opportunity Announcement (FOA) is to encourage new research into the complexity of cancer by fostering new interactions with two existing and related programs within the NCI: the Integrative Cancer Biology Program (ICBP) and/or the Tumor Microenvironment Network (TMEN). The NCI specifically encourages new collaborative projects between investigators associated with the ICBP or TMEN and researchers who are not involved with the program with which they propose to collaborate. For this goal, applicants are strongly encouraged to take advantage of the multiple Project Directors/Principal Investigators (PDs/PIs) option, with at least one PD/PI representing ICBP or TMEN and at least one being currently non-affiliated investigator. The themes of these projects must be relevant to the general mission of the ICBP or TMEN. In particular, the proposed projects are expected to bring new expertise, methods, ideas, and resources to the fields of integrative cancer biology and tumor microenvironment research.
Enormous progress has been made in understanding the genetic, molecular, and cellular components of cancer. In cancer, the systems which are normally held in check by various homeostatic processes no longer function properly. It is for this reason that a basic understanding of critical cellular processes, such as cell cycle, DNA repair, apoptosis, transcription, cell migration, and matrix structure, is so critical to our understanding and treatment of cancer. However, cancer is not a disease only of cells. It is a disease of various systems and components that interact at both a molecular and cellular level to lead to initiation and progression of the disease. These interacting systems include interactions between genes in the cancer cells, between signal transduction pathways within a cancer cell, between cells in the tumor, between the tumor and its microenvironment, and between the individual and the macro-environment. Furthermore, the changing interactions of these various systems in a very dynamic environment underscore the inherent complexity of the disease. Until recently, it has been necessary to apply a reductionist approach to cancer research, focusing on a specific mutation, signaling pathway, or cell. While there has been remarkable progress in understanding each of these component parts, further integration across components or scales has been limited primarily by the lack of technology and tools needed to interrogate at any higher level.
Within the past 10 years, new technologies have been developed that have generated extensive genomic, proteomic and other genome-wide datasets. Other novel technologies have made possible vital imaging, isolation of rare cells, and organotypic culturing. Together, these developments have afforded the possibility to expand the cancer research effort to include an integrative systems approach.
To encourage and support the development of this new integrative research approach, the NCI has implemented two programs specifically targeted at addressing and examining the complexity of cancer: The Integrative Cancer Biology Program (ICBP) and the Tumor Micro-Environment Network (TMEN).
The ICBP is composed of multi-disciplinary centers focused on the development of predictive computational models of cancer which vary in the biological aspect of cancer as well as the computational or mathematical modeling approaches they are developing. Each center functions independently as well as working together on cross cutting biological and computational approaches. The program also functions as an educational and research resource for the cancer community (http://icbp.nci.nih.gov/).
The TMEN program is composed of multi-disciplinary centers focused on understanding cancer as complex disease of various cell types and environments (http://tmen.nci.nih.gov/). The overall TMEN goal is to achieve a high-level understanding of stromal composition and tumor-stromal interactions in clinically important tumor sites. In addition to high scientific productivity of individual research programs, this goal requires ensuring that results, ideas, and resources are shared freely within the Network, promoting trans-Network collaborative projects.
In the course of their research and outreach activities, the component ICBP and TMEN centers have also created a community of investigators with expertise in these emerging integrative areas and a compendium of resources that includes reagents, software, and other tools. Through this new initiative, individual investigators not affiliated are invited to collaborate with investigators affiliated with one of the programs, thereby extending the programs to a wider community.
This FOA is designed to facilitate new projects in integrative cancer biology and/or tumor microenvironment research and to extend current research conducted in the ICBP and TMEN programs through collaborations with the broader research community. Projects proposed in response to this FOA should be collaborative , and relevant to the ICBP or TMEN missions. In addition to proposing new research, these projects should leverage the resources and expertise available in the ICBP and TMEN and extend and enhance the focus of the ICBP and TMEN with new ideas, methods, expertise, and resources. A broad range of potential collaborative projects are possible. In particular, these collaborations present an opportunity for investigators with expertise in other biological systems or organ sites not currently being modeled or studied within the ICBP or TMEN centers and investigators from complementary disciplines such as applied mathematics and engineering to work with ICBP or TMEN investigators to propose new projects in integrative cancer biology or tumor microenvironment research. The proposed projects may build on current ICBP and TMEN programs and/or efforts but should not overlap.
Interested researchers, not currently affiliated with the program they are proposing to collaborate with, should consult the list of key investigators from the ICBP and TMEN programs designated by the ICBP and TMEN centers posted on the following websites:
Collaborating teams composed of at least one ICBP or TMEN PD/PI and at least one non-affiliated PD/PI are eligible to propose projects to thisFOA. Projects supported through this FOA will be affiliated with the ICBP or TMEN. Project PDs/PIs or other key personnel are invited to participate in ICBP or TMEN events relevant to the scope of their projects, including relevant ICBP and TMEN semi-annual PD/PI meetings.
Projects proposed should be new and should be aligned with the overall mission of the program, ICBP or TMEN. Below are examples of the types of collaborative research projects this FOAwould support. This list shows possible examples but is not all inclusive. Any project which is within the mission of the ICBP or TMEN and fits the other criteria outlined in this FOA will be considered.
Examples of possible ICBP collaborative projects:
Cooperative Agreement: A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, scientific or program staff will assist, guide, coordinate, or participate in project activities.
Application Types Allowed
The OER Glossary and the SF 424 (R&R) Application Guide provide details on these application types.
Funds Available and Anticipated Number of Awards
The number of awards is contingent upon NIH appropriations, and the submission of a sufficient number of meritorious applications.
Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size of each award will also vary.
Application Budgets for direct costs up to $500,000 per year and project duration of up to 5 years may be requested.
Award Project Period
Scope of the proposed project should determine the project period. The maximum period is 5 years.
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.
Higher Education Institutions:
The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
Nonprofits Other Than Institutions of Higher Education
For profit Organizations
Foreign (non-U.S.) components of U.S. Organizations are allowed.
Applicant organizations must complete the following registrations
as described in the SF 424 (R&R) Application Guide to be eligible to apply
for or receive an award. Applicants must have a valid Dun and Bradstreet
Universal Numbering System (DUNS) number in order to begin each of the following
All Program Directors/Principal Investigators (PD/PIs) must
also work with their institutional officials to register with the eRA Commons
or ensure their existing eRA Commons account is affiliated with the eRA Commons
account of the applicant organization.
All registrations must be completed by the application due date. Applicant organizations are strongly encouraged to start the registration process at least four (4) weeks prior to the application due date.
Any individual(s) with the skills, knowledge, and resources
necessary to carry out the proposed research as the Program Director/Principal
Investigator (PD/PI) is invited to work with his/her organization to develop an
application for support. Individuals from underrepresented racial and ethnic
groups as well as individuals with disabilities are always encouraged to apply
for NIH support.
For the goals of this FOA, applicants are strongly encouraged to take advantage of the multiple PDs/PIs option.
For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF 424 (R&R) Application Guide.
This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
NIH will not accept any application in response to this FOA that is essentially the same as one currently pending initial peer review unless the applicant withdraws the pending application. NIH will not accept any application that is essentially the same as one already reviewed. Resubmission applications may be submitted, according to the NIH Policy on Resubmission Applications from the SF 424 (R&R) Application Guide.
Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the “Apply for Grant Electronically” button in this FOA or following the directions provided at Grants.gov.
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:
Descriptive title of proposed research
Name, address, and telephone number of the PD(s)/PI(s)
Names of other key personnel
Number and title of this funding opportunity
The letter of intent should be sent to:
Jennifer Couch, Ph.D.
Chief, Structural Biology and Molecular Applications Branch
Division of Cancer Biology
National Cancer Institute
6130 Executive Boulevard, EPN Room 5000, MSC 7385
Bethesda, MD 20892-7385 (for U.S. Postal Service express or regular mail)
Rockville, MD 20852 (for non-U.S.P.S. delivery)
Telephone: (301) 435-5226
Fax: (301) 480-2854
The forms package associated with this FOA includes all applicable components, mandatory and optional. Please note that some components marked optional in the application package are required for application submission. Follow all instructions in the SF424 (R&R) Application Guide to ensure you complete all appropriate “optional” components.
All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:
Participation of Collaborative Research Awardees in the Activities of ICBP and TMEN Consortia.
Collaborative Research U01 Awardees will be expected to participate in the activities of ICBP and TMEN consortia (as appropriate to their projects) and to adhere to the recommendations and standard procedures established by the respective Steering Committees of ICBP and TMEN consortia.
Specifically, investigators submitting applications to this FOA must plan for the following activities:
Resource Sharing Plan
Individuals are required to comply with the instructions for the Resource Sharing Plans (Data Sharing Plan, Sharing Model Organisms, and Genome Wide Association Studies (GWAS)) as provided in the SF424 (R&R) Application Guide.
Do not use the appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
Foreign (non-US) organizations must follow policies described in the NIH Grants Policy Statement, and procedures for foreign organizations described throughout the SF424 (R&R) Application Guide.
Part I. Overview Information contains information about Key Dates. Applicants are encouraged to submit in advance of the deadline to ensure they have time to make any application corrections that might be necessary for successful submission.
Organizations must submit applications via Grants.gov, the online portal to find and apply for grants across all Federal agencies. Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration.
Applicants are responsible for viewing their application in the eRA Commons to ensure accurate and successful submission.
Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.
This initiative is not subject to intergovernmental review.
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable only as described in the NIH Grants Policy Statement.
Applications must be submitted electronically following the instructions described in the SF 424 (R&R) Application Guide. Paper applications will not be accepted.
Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.
For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically.
All PD/PIs must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF 424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH.
The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization’s profile in the eRA Commons and for the Central Contractor Registration (CCR). Additional information may be found in the SF424 (R&R) Application Guide.
See more tips for avoiding common errors.
Upon receipt, applications will be evaluated for completeness by the Center for Scientific Review, NIH. Applications that are incomplete will not be reviewed.
Applicants are required to follow the instructions for post-submission materials, as described in NOT-OD-10-115.
Only the review criteria described below will be considered in the review process. As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.
Reviewers will provide an overall impact/priority score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).
Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.
Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
Are the PD/PIs, collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
In addition, specific to this FOA.
Does the PD/PI who is currently not affiliated with ICBP or TMEN bring additional expertise or resources that will enhance the scope of research or other activities conducted in the ICBP or TMEN?
Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
In addition, specific to this FOA.
Will this project serve as a model for cross-disciplinary studies?
the overall strategy, methodology, and analyses well-reasoned and appropriate
to accomplish the specific aims of the project? Are potential problems,
alternative strategies, and benchmarks for success presented? If the project is
in the early stages of development, will the strategy establish feasibility and
will particularly risky aspects be managed?
If the project involves clinical research, are the plans for 1) protection of human subjects from research risks, and 2) inclusion of minorities and members of both sexes/genders, as well as the inclusion of children, justified in terms of the scientific goals and research strategy proposed?
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact/priority score, but will not give separate scores for these items.
Protections for Human Subjects
For research that involves human subjects but does
not involve one of the six categories of research that are exempt under 45 CFR
Part 46, the committee will evaluate the justification for involvement of human
subjects and the proposed protections from research risk relating to their
participation according to the following five review criteria: 1) risk to
subjects, 2) adequacy of protection against risks, 3) potential benefits to the
subjects and others, 4) importance of the knowledge to be gained, and 5) data
and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Human Subjects Protection and Inclusion Guidelines.
Inclusion of Women, Minorities, and Children
When the proposed project involves clinical research, the committee will evaluate the proposed plans for inclusion of minorities and members of both genders, as well as the inclusion of children. For additional information on review of the Inclusion section, please refer to the Human Subjects Protection and Inclusion Guidelines.
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.
For Revisions, the committee will consider the appropriateness of the proposed expansion of the scope of the project. If the Revision application relates to a specific line of investigation presented in the original application that was not recommended for approval by the committee, then the committee will consider whether the responses to comments from the previous scientific review group are adequate and whether substantial changes are clearly evident.
As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact/priority score.
Applications from Foreign Organizations
Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.
Select Agent Research
Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Resource Sharing Plans
Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 1) Data Sharing Plan; 2) Sharing Model Organisms; and 3) Genome Wide Association Studies (GWAS).
Budget and Period of Support
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
Applications will be evaluated for scientific and technical
merit by (an) appropriate Scientific Review Group(s) , in accordance with NIH
peer review policy and procedures, using the stated review
criteria. Review assignments will be shown in the eRA Commons.
As part of the scientific peer review, all applications:
Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications in response to this FOA. Following initial peer review, recommended applications will receive a second level of review by the National Cancer Advisory Board.. The following will be considered in making funding decisions:
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons.
Information regarding the disposition of applications is available in the NIH Grants Policy Statement.
If the application is under consideration for funding, NIH
will request "just-in-time" information from the applicant as
described in the NIH Grants
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee business official.
Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.
Any application awarded in response to this FOA will be subject to the DUNS, CCR Registration, and Transparency Act requirements as noted on the Award Conditions and Information for NIH Grants website.
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.
Cooperative Agreement Terms and Conditions of Award
The following special terms of award are in addition to, and
not in lieu of, otherwise applicable OMB administrative guidelines, HHS grant
administration regulations at 45 CFR Parts 74 and 92 (Part 92 is applicable
when State and local Governments are eligible to apply), and other HHS, PHS,
and NIH grant administration policies.
The administrative and funding instrument used for this program will be the cooperative agreement, an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the awardees is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipients' activities by involvement in and otherwise working jointly with the award recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the awardees for the project as a whole, although specific tasks and activities may be shared among the awardees and the NIH as defined below.
The PD(s)/PI(s) will have the primary responsibility for:
The PD(s)/PI(s) will have primary authority and responsibility to define objectives and approaches, and to plan, conduct, analyze, and publish results, interpretations, and conclusions of studies conducted under this program. The PD(s)/PI(s) assume responsibility and accountability to the applicant organization officials and to the NCI for the performance and proper conduct of the research supported by the U01 award in accordance with these terms and conditions of the award.
Specific rights and responsibilities of the PD(s)/PI(s) will include the following:
Awardees will retain custody of and have primary rights to the data and software developed under these awards, subject to Government rights of access consistent with current HHS, PHS, and NIH policies.
NIH staff have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:
A designated NCI Program Director acting as a Project Scientist will have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below. The NCI Project Scientist will not attend peer review meetings of renewal (competing continuation) and/or supplemental applications. If such participation is essential, these individuals will seek NCI waiver according to the NCI procedures for management of conflict of interest.
Specifically, the NCI Project Scientists will:
Additionally, an NCI Program Director acting as the Program Official will be responsible for the normal scientific and programmatic stewardship of the awards and will be named in the award notice. A Program Official may also have substantial programmatic involvement (as a Project Scientist) and may be the same person as Project Scientist. In that case, the individual involved will not attend peer review meetings of renewal (competing continuation) and/or supplemental applications, or will seek NCI waiver.
Areas of Joint Responsibility include:
The NCI Project Scientist and the PD/PIs of the U01 awards funded under the Collaborative Research in Cancer Biology program will be jointly responsible for the coordination of intra-program activities and the scientific integration of individual projects with either ICBP or TMEN.
Although the Collaborative Research program will not have any separate formal governing body, these activities may involve the formation of two Coordination Groups (CG), one for those projects affiliated with ICBP, and a second for those affiliated with TMEN. The primary role of CG will be to serve as interface between the individual Collaborative Research projects and the ICBP or TMEN programs and to facilitate reaching consensus with regard to the integration of research efforts.
CG will include senior representatives of each U01 project, the NCI Project Scientist, and, if desirable, other NCI staff members involved in the ICBP or TMEN program. Meetings of the CG may be virtual or by teleconference.
The NCI Project Scientist will initiate the formation of the CG and will facilitate its activities. .
The affiliation of the Cooperative Research awardees with the ICBP or TMEN program and their participation (along with Cooperative Research Project Scientist), invited members on the ICBP or TMEN Steering Committees will provide the main venue for joint activities between the awardees and the NCI.
Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between award recipients and the NIH may be brought to Dispute Resolution. A Dispute Resolution Panel composed of three academic members who are not involved in the study will be convened. This special dispute resolution procedure does not alter the awardee's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulation 42 CFR Part 50, Subpart D and DHHS regulation 45 CFR Part 16.
When multiple years are involved, awardees will be required to submit the Non-Competing Continuation Grant Progress Report (PHS 2590) annually and financial statements as required in the NIH Grants Policy Statement.
A final progress report, invention statement, and Financial Status Report are required when an award is relinquished when a recipient changes institutions or when an award is terminated.
The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.
We encourage inquiries concerning this funding opportunity
and welcome the opportunity to answer questions from potential applicants.
GrantsInfo (Questions regarding application instructions and
process, finding NIH grant resources)
eRA Commons Help Desk(Questions regarding eRA Commons registration,
tracking application status, post submission issues)
Phone: 301-402-7469 or 866-504-9552 (Toll Free)
Questions related to ICBP collaborations:
Jennifer Couch, Ph.D.
Division of Cancer Biology (DCB)
National Cancer Institute (NCI)
6130 Executive Boulevard, EPN Room 5000, MSC 7385
Bethesda, MD 20892-7385 (for U.S. Postal Service Express or regular mail)
Rockville, MD 20852 (for non-USPS delivery)
Telephone: (301) 435-5226
Fax: (301) 480-2854
Questions related to TMEN collaborations:
Suresh Mohla, Ph.D.
Division of Cancer Biology (DCB)
National Cancer Institute (NCI)
6130 Executive Boulevard, EPN Room 5038, MSC 7364
Bethesda, MD 20892-7364 (for U.S. Postal Service Express or regular mail)
Rockville, MD 20852 (for non-USPS delivery)
Telephone: (301) 435-1878
Fax: (301) 480-0864
National Cancer Institute
Division of Extramural Activities
6116 Executive Boulevard, Room 8041, MSC 8329
Bethesda, MD 20892-8329 (for U.S. Postal Service express or regular mail)
Rockville MD 20852 (for non-USPS delivery)
Telephone: (301) 496-3428
Fax: (301) 402-0275
Office of Grants Administration
National Cancer Institute
6120 Executive Boulevard, EPS Suite 243, MSC 7150
Bethesda, MD 20892-7150 (for U.S. Postal Service express or regular mail)
Rockville, MD 20852 (for express/courier delivery)
Telephone: (301) 496-8634
Fax: (301) 496-8601
Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Parts 74 and 92.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Department of Health
and Human Services (HHS)
NIH... Turning Discovery Into Health®
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.